City Therapeutics, a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, and Biogen today announced a strategic collaboration to develop select novel RNAi therapies. City Therapeutics is one of AN Venture Partners’ portfolio companies.

Through the collaboration, City Therapeutics will leverage its next-generation RNAi engineering technologies to develop an RNAi trigger molecule combined with proprietary drug delivery technology from Biogen. The collaboration will initially focus on a single target that mediates key central nervous system diseases, utilizing tissue enhanced delivery technologies with the aim of allowing for systemic administration of medicines. Biogen will be responsible for IND-enabling studies and global clinical development along with any regulatory submissions and all activities related to commercialization.

For the full announcement, please see City Therapeutics’ press release here.

 
About AN Venture Partners

ANV is a Tokyo and San Francisco-based biotech venture capital firm. ANV is dedicated to building high impact global biotech companies and specializes in sourcing scientific opportunities from Japan.

Media Contacts
Email: info@an.vc